Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study
Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study
To assess, under daily practice conditions, the safety profile and the efficacy of a new
 formulation of alfuzosin administered once daily (Xatral XL) in patients with lower urinary
 tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
Inclusion Criteria:

 -  Ambulatory patients suffering from lower urinary tract symptoms suggestive of BPH.

 Exclusion Criteria:

 -  Patients requiring BPH surgery immediately or within the 12 following months:

 -  Acute renal obstruction

 -  Chronic renal obstruction

 -  Chronic renal failure from BPH

 -  Bladder stone

 -  Recurrent urinary tract infection

 -  Other bladder pathology such as cancer of the bladder, bladder bidiverticulum
 (big size)

 -  Hematuria from BPH

 -  Patients whose urinary symptoms are satisfactorily controlled on other BPH medication
 ( alpha-blockers or 5 alpha-reductase)

 -  Patients previously not improved by an alpha1-blocker treatment

 -  Known hypersensitivity to alfuzosin

 -  History of postural hypotension or syncope

 -  Combination with other alpha1-blockers

 -  Hepatic enzyme (SGOT or/and SGPT ) > 1.5 Upper Normal Limit

 -  Unstable angina pectoris

 -  Severe concomitant condition threatening life.

 -  Patients who had failed treatment with finasteride (Proscar)

 -  Patients with neuropathic bladder.

 -  Patients with history of previous surgery for BPH

 -  Patients with high risk for prostate cancer based on the clinical judgement of the
 investigator

 The above information is not intended to contain all considerations relevant to a patient's
 potential participation in a clinical trial.